QuiaPEG Pharmaceuticals Holding AB (ST:QUIA) — Market Cap & Net Worth
Market Cap & Net Worth: QuiaPEG Pharmaceuticals Holding AB (QUIA)
QuiaPEG Pharmaceuticals Holding AB (ST:QUIA) has a market capitalization of $141.00K (Skr1.31 Million) as of August 5, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #31268 globally and #739 in its home market, demonstrating a -44.44% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying QuiaPEG Pharmaceuticals Holding AB's stock price Skr0.00 by its total outstanding shares 2620377659 (2.62 Billion). See QuiaPEG Pharmaceuticals Holding AB (QUIA) reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
QuiaPEG Pharmaceuticals Holding AB Market Cap History: 2015 to 2025
QuiaPEG Pharmaceuticals Holding AB's market capitalization history from 2015 to 2025. Data shows change from $84.03 Billion to $141.00K (-71.82% CAGR).
Index Memberships
QuiaPEG Pharmaceuticals Holding AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.92 Billion | 0.00% | #257 of 281 |
Weight: QuiaPEG Pharmaceuticals Holding AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
QuiaPEG Pharmaceuticals Holding AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how QuiaPEG Pharmaceuticals Holding AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.44x
QuiaPEG Pharmaceuticals Holding AB's market cap is 6.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $84.03 Billion | $14.40 Million | $578.00K | 5835.44x | 145381.23x |
| 2016 | $91.42 Billion | $916.00K | $9.60 Million | 99805.39x | 9528.06x |
| 2017 | $20.11 Billion | $3.93 Million | -$4.47 Million | 5114.13x | N/A |
| 2018 | $45.12 Billion | $3.38 Million | -$12.05 Million | 13361.59x | N/A |
| 2019 | $45.98 Billion | $4.47 Million | -$21.11 Million | 10295.65x | N/A |
| 2020 | $21.88 Billion | $1.86 Million | -$27.71 Million | 11754.72x | N/A |
| 2021 | $7.52 Billion | $216.00K | -$22.43 Million | 34833.63x | N/A |
| 2022 | $1.81 Billion | $5.57 Million | -$24.38 Million | 324.96x | N/A |
| 2023 | $18.64 Million | $4.37 Million | -$16.52 Million | 4.26x | N/A |
| 2024 | $2.96 Million | $460.00K | -$28.93 Million | 6.44x | N/A |
Competitor Companies of QUIA by Market Capitalization
Companies near QuiaPEG Pharmaceuticals Holding AB in the global market cap rankings as of August 5, 2026.
Key companies related to QuiaPEG Pharmaceuticals Holding AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
QuiaPEG Pharmaceuticals Holding AB Historical Marketcap From 2015 to 2025
Between 2015 and today, QuiaPEG Pharmaceuticals Holding AB's market cap moved from $84.03 Billion to $ 141.00K, with a yearly change of -71.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Skr141.00K | -95.24% |
| 2024 | Skr2.96 Million | -84.11% |
| 2023 | Skr18.64 Million | -98.97% |
| 2022 | Skr1.81 Billion | -75.93% |
| 2021 | Skr7.52 Billion | -65.61% |
| 2020 | Skr21.88 Billion | -52.42% |
| 2019 | Skr45.98 Billion | +1.90% |
| 2018 | Skr45.12 Billion | +124.39% |
| 2017 | Skr20.11 Billion | -78.00% |
| 2016 | Skr91.42 Billion | +8.80% |
| 2015 | Skr84.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of QuiaPEG Pharmaceuticals Holding AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $141.00K USD |
| MoneyControl | $141.00K USD |
| MarketWatch | $141.00K USD |
| marketcap.company | $141.00K USD |
| Reuters | $141.00K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About QuiaPEG Pharmaceuticals Holding AB
Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as… Read more